Several studies have demonstrated the efficacy of PARP inhibitors in women with and without BRCA1/2 germline mutations, particularly when they are used as both single agents and maintenance therapy for the treatment of platinum-sensitive recurrent serous ovarian cancer with consistent findings of significant increases in progression-free survival (PFS) [12, 15–20]. Here, PARP1 is linked to ovarian serous adenocarcinoma.